Intravesical ALT-803 for BCG-unresponsive Bladder Cancer – A Case Report

Sylvester, 2011, Bacillus Calmette-Guerin treatment of non-muscle invasive bladder cancer, Int J Urol, 18, 113, 10.1111/j.1442-2042.2010.02678.x Herr, 2000, Tumor progression and survival of patients with high grade, noninvasive papillary (TaG3) bladder tumors: 15-year outcome, J Urol, 163, 60 Montecino-Rodriguez, 2013, Causes, consequences, and reversal of immune system aging, J Clin Invest, 123, 958, 10.1172/JCI64096 Gomes-Giacoia, 2014, Intravesical ALT-803 and BCG treatment reduces tumor burden in a carcinogen induced bladder cancer rat model; a role for cytokine production and NK cell expansion, PLoS One, 9, e96705, 10.1371/journal.pone.0096705 Waldmann, 2006, The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design, Nat Rev Immunol, 6, 595, 10.1038/nri1901 Rhode, 2016, Comparison of the superagonist complex, ALT-803, to IL15 as cancer immunotherapeutics in animal models, Cancer Immunol Res, 4, 49, 10.1158/2326-6066.CIR-15-0093-T